NewGenIvf Group Limited
NIVF Healthcare Medical Care Facilities
NewGenIvf Group Limited’s revenue for fiscal 2025 (year ended December 2025) was $4.7 million, down 13.0% from fiscal 2024. Dividend growth for five consecutive years; insiders bought in the last twelve months.
Follow NIVF
NewGenIvf Group Limited (NIVF) Piotroski F-score
NewGenIvf Group Limited's Piotroski F-score for fiscal 2025 cannot be worked out: shares outstanding not reported.
Piotroski F-score, annual
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 54.43% | (13.01%) | Pass | 1 |
| Positive operating cash flow | (10.93m) | (8.26m) | Fail | 0 |
| Rising return on assets | 54.43% | (13.01%) | Pass | 1 |
| Cash flow above net income | (20.81m) | (7.74m) | Fail | 0 |
| Falling long-term leverage | 0.23 | 0.58 | Pass | 1 |
| Rising current ratio | 3.12 | 1.17 | Pass | 1 |
| No new shares issued | 5,100 | — | n/a | — |
| Rising gross margin | 20.22% | 33.62% | Fail | 0 |
| Rising asset turnover | 0.26 | 1.35 | Fail | 0 |
| Piotroski F-score | n/a — shares outstanding not reported | — | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| CCM Concord Medical Services Holdings Limited compare | 6 |
| RHEP Adcare Health Systems Inc compare | 5 |
| SYRA Syra Health Corp. compare | 5 |
| MODVQ ModivCare Inc. compare | 3 |
| CANOQ Cano Health, Inc. compare | 3 |
| NVOS Novo Integrated Sciences, Inc. compare | 3 |
| AMS American Shared Hospital Services compare | 3 |
| NIVF NewGenIvf Group Limited | — |
| BMGL Basel Medical Group Ltd compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover